Patents by Inventor Mingming Zou

Mingming Zou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 12478608
    Abstract: The present invention relates to use of slow-releasing hydrogen sulfide organic donor ADT-OH drugs in the differentiation of neural precursor cells. ADT-OH can induce more directed differentiation of neural precursor cells into neurons and oligodendrocytes and less differentiation into astrocytes, promote the axon growth of neurons, and reduce the death of neural precursor cells, thereby providing a direction for the transplantation of neural precursor cells to repair damaged nerves. ADT-OH will likely become a new drug target for the clinical treatment of nervous system diseases.
    Type: Grant
    Filed: October 9, 2021
    Date of Patent: November 25, 2025
    Assignee: SOOCHOW UNIVERSITY
    Inventors: Yanxia Ma, Shanwen Wei, Mingming Zou, Li Ni, Liyu Zhou, Di Li, Yanwei Yang
  • Publication number: 20230355576
    Abstract: The present invention relates to use of slow-releasing hydrogen sulfide organic donor ADT-OH drugs in the differentiation of neural precursor cells. ADT-OH can induce more directed differentiation of neural precursor cells into neurons and oligodendrocytes and less differentiation into astrocytes, promote the axon growth of neurons, and reduce the death of neural precursor cells, thereby providing a direction for the transplantation of neural precursor cells to repair damaged nerves. ADT-OH will likely become a new drug target for the clinical treatment of nervous system diseases.
    Type: Application
    Filed: October 9, 2021
    Publication date: November 9, 2023
    Inventors: Yanxia MA, Shanwen WEI, Mingming ZOU, Li NI, Liyu ZHOU, Di LI, Yanwei YANG
  • Patent number: 9861703
    Abstract: The present invention relates to the design, synthesis, and biological study of multi-targeted Ubenimex pro-drug derivative. More particularly, provided in the present invention is a compound as shown by general structural formula (I) (wherein the definition of R is shown in the description). The derivative is a multi-targeted compound obtained by binding an aminopeptidase (APN/CD13) inhibitor, Ubenimex, with some anti-tumor drugs already on the market through an ester bond or amide bond, and is suitable for use as an anti-tumor drug for the treating various malignant tumors, and is especially suitable for treating various solid tumors.
    Type: Grant
    Filed: June 6, 2014
    Date of Patent: January 9, 2018
    Assignee: Jinan Platinum Pharmatech Co. Ltd.
    Inventors: Wenfang Xu, Yuqi Jiang, Yingjie Zhang, Mingming Zou, Jinning Hou, Jin Li, Xuejian Wang, Xiaoyang Li
  • Publication number: 20160193347
    Abstract: The present invention relates to the design, synthesis, and biological study of multi-targeted Ubenimex pro-drug derivative. More particularly, provided in the present invention is a compound as shown by general structural formula (I) (wherein the definition of R is shown in the description). The derivative is a multi-targeted compound obtained by binding an aminopeptidase (APN/CD13) inhibitor, Ubenimex, with some anti-tumor drugs already on the market through an ester bond or amide bond, and is suitable for use as an anti-tumor drug for the treating various malignant tumors, and is especially suitable for treating various solid tumors.
    Type: Application
    Filed: June 6, 2014
    Publication date: July 7, 2016
    Applicant: WEIFANG BOCHUANG INTERNATIONAL ACADEMY OF BIOTECHNOLOGY AND MEDICINE
    Inventors: Wenfang Xu, Yuqi Jiang, Yingjie Zhang, Mingming Zou, Jinning Hou, Jin Li, Xuejian Wang, Xiaoyang Li